[Abstract] [Full Text HTML] [Full Text PDF] (in Japanese / 539KB) [Members Only]

J.Jpn. Surg. Soc.. 119(3): 293-298, 2018

Feature topic


1) Department of Breast and Endocrine Surgery, the University of Tokyo Graduate School of Medicine, Tokyo, Japan
2) Department of Gastrointestinal Surgery, the University of Tokyo Graduate School of Medicine, Tokyo, Japan
3) Center of Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
4) Department of Pathology, the University of Tokyo Hospital, Tokyo, Japan
5) JCHO Tokyo Medical Center, Tokyo, Japan
6) Breast Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan
7) Preventive Medicine, NTT Medical Center Tokyo, Tokyo, Japan
8) Gastroenterology, NTT Medical Center Tokyo, Tokyo, Japan
9) Otsuka Pharmaceutical Tokushima Research Institute, Tokushima, Japan
10) Breast Center, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan
11) Breast and Endocrine Surgery, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan

Yuko Ishibashi1), Yasuko Kikuchi1), Takayoshi Niwa1)5), Kotoe Nishioka1), Hiroshi Ohtsu3), Masako Ikemura4), Yoshihiro Uchida6), Hirona Miura2), Susumu Aikou2), Toshiaki Gunji7), Nobuyuki Matsuhashi8), Yasukazu Ohmoto9), Takeshi Sasaki4), Toshihisa Ogawa10), Keiichiro Tada1)11), Yasuyuki Seto2), Masahiko Tanabe1), Sachiyo Nomura2)

Breast cancer remains a common malignancy in women, but the participation rate in breast cancer screening programs in Japan is still low, possibly due to their perceived inconvenience. Breast cancer screening with mammography or ultrasound is provided for women beginning at 40 years of age by local governments in Japan. If breast cancer could be screened through a blood test instead of mammography or ultrasound, the participation rate in screening examinations would likely increase. Trefoil factors (TFFs) are small, stable peptides secreted by the mammalian epithelial mucous-secreting cells in the gastrointestinal tract. TFFs constitute a family of three peptides (TFF1, TFF2, and TFF3) that are widely expressed in a tissue-specific manner in the body. Serum TFF1 and TFF3 levels were found to be significantly higher and serum TFF2 levels significantly lower in breast cancer patients. The area under the curve (AUC) of receiver operating characteristics of TFF1, TFF2, and TFF3 was 0.69, 0.83, and 0.72, respectively. The AUC of the combination of TFF1, TFF2, and TFF3 was 0.96. Serum TFFs are therefore significant biomarkers for breast cancer screening.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.